1. Home
  2. SOTK vs GANX Comparison

SOTK vs GANX Comparison

Compare SOTK & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sono-Tek Corporation

SOTK

Sono-Tek Corporation

HOLD

Current Price

$5.39

Market Cap

73.7M

Sector

Technology

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.70

Market Cap

78.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOTK
GANX
Founded
1975
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.7M
78.2M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
SOTK
GANX
Price
$5.39
$1.70
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
40.6K
697.2K
Earning Date
05-27-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
37.50
31.46
EPS
0.11
N/A
Revenue
$20,909,315.00
$55,180.00
Revenue This Year
$4.02
N/A
Revenue Next Year
$10.95
N/A
P/E Ratio
$47.91
N/A
Revenue Growth
1.97
N/A
52 Week Low
$3.23
$1.41
52 Week High
$5.74
$4.34

Technical Indicators

Market Signals
Indicator
SOTK
GANX
Relative Strength Index (RSI) 56.19 43.47
Support Level $3.79 $1.65
Resistance Level $5.72 $2.12
Average True Range (ATR) 0.39 0.13
MACD -0.02 -0.01
Stochastic Oscillator 65.29 26.53

Price Performance

Historical Comparison
SOTK
GANX

About SOTK Sono-Tek Corporation

Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: